UroGen Pharma (URGN) Depreciation & Amortization (CF) (2018 - 2026)
UroGen Pharma's (URGN) quarterly Depreciation & Amortization (CF) came in at $100000.0 in Q1 2026, little changed YoY from $100000.0 in Q1 2025, and up 33.33% on a QoQ basis from $75000.0 in Q4 2025.
Powered by 
Analysis
UroGen Pharma (URGN) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $100000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $375000.0 (up 13.98% YoY) and the FY2025 annual result came in at $307000.0, down 6.69% from the prior year.
- Depreciation & Amortization (CF) rose to $100000.0 in Q1 2026, from $75000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $224000.0 in Q4 2022 to a low of $29000.0 in Q4 2024.
- A 5-year average of $145470.6 and a median of $123000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) tumbled 84.74% — and 2025, when it jumped 158.62%.
- Tracing URGN's Depreciation & Amortization (CF) over 5 years: stood at $224000.0 in 2022, then decreased by 15.18% to $190000.0 in 2023, then plunged by 84.74% to $29000.0 in 2024, then jumped by 158.62% to $75000.0 in 2025, then jumped by 33.33% to $100000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $100000.0 (Q1 2026), $75000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | 100,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 75,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 29,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Dec 31, 2023 | 190,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Mar 31, 2023 | 217,000.00 |
| Dec 31, 2022 | 224,000.00 |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 200,000.00 |
| Mar 31, 2022 | 215,000.00 |
| Dec 31, 2021 | 213,000.00 |
| Sep 30, 2021 | 200,000.00 |